Compare GHRS & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GHRS | PBH |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2021 | 2004 |
| Metric | GHRS | PBH |
|---|---|---|
| Price | $18.22 | $50.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $42.89 | ★ $67.80 |
| AVG Volume (30 Days) | 299.1K | ★ 548.8K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $975,777,000.00 |
| Revenue This Year | N/A | $17.03 |
| Revenue Next Year | N/A | $6.06 |
| P/E Ratio | ★ N/A | $80.70 |
| Revenue Growth | N/A | ★ 36.77 |
| 52 Week Low | $12.04 | $42.62 |
| 52 Week High | $31.44 | $71.07 |
| Indicator | GHRS | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 22.04 | 60.51 |
| Support Level | $13.58 | $49.73 |
| Resistance Level | $22.88 | $51.57 |
| Average True Range (ATR) | 1.19 | 1.22 |
| MACD | -0.33 | 0.52 |
| Stochastic Oscillator | 2.31 | 85.48 |
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.